دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation
Philipp Lurz, Ralph Stephan von Bardeleben, Marcel Weber, Marta Sitges, ... Georg Nickenig
doi : 10.1016/j.jacc.2020.11.038
Volume 77, Issue 3, 26 January 2021, Pages 229-239
Tricuspid regurgitation (TR) is a frequent disease with a progressive increase in mortality as disease severity increases. Transcatheter therapies for treatment of TR may offer a safe and effective alternative to surgery in this high-risk population.
Are We Right to Believe in the Value of Transcatheter Treatment of Secondary Tricuspid Regurgitation?
Erwan Donal, Guillaume Leurent, Bernard Iung
doi : 10.1016/j.jacc.2020.11.037
Volume 77, Issue 3, 26 January 2021, Pages 240-242
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Carlos G. Santos-Gallego, Ariana P. Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, ... Juan J. Badimon
doi : 10.1016/j.jacc.2020.11.008
Volume 77, Issue 3, 26 January 2021, Pages 243-255
Large clinical trials established the benefits of sodium-glucose cotransporter 2 inhibitors in patients with diabetes and with heart failure with reduced ejection fraction (HFrEF). The early and significant improvement in clinical outcomes is likely explained by effects beyond a reduction in hyperglycemia.
The Pleiotropic Effects of SGLT2 Inhibitors: Remodeling the Treatment of Heart Failure
Lee R. Goldberg
doi : 10.1016/j.jacc.2020.11.029
Volume 77, Issue 3, 26 January 2021, Pages 256-258
Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization
Kazuma Oyama, Remo H.M. Furtado, Antonio Fagundes, Thomas A. Zelniker, ... Brian A. Bergmark
doi : 10.1016/j.jacc.2020.11.011
Volume 77, Issue 3, 26 January 2021, Pages 259-267
This study sought to evaluate the ability of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to reduce the risk of complex coronary atherosclerosis requiring revascularization.
Cholesterol Lowering and Coronary Revascularization: Finally a Marriage to Sustain?
E. Magnus Ohman, Michael G. Nanna
doi : 10.1016/j.jacc.2020.11.036
Volume 77, Issue 3, 26 January 2021, Pages 268-270
Short-Term Exposure to Ambient Air Pollution and Mortality From Myocardial Infarction
Yuewei Liu, Jingju Pan, Chuangang Fan, Ruijun Xu, ... Lan Zhang
doi : 10.1016/j.jacc.2020.11.033
Volume 77, Issue 3, 26 January 2021, Pages 271-281
Short-term exposure to ambient air pollution has been linked to occurrence of myocardial infarction (MI); however, only a limited number of studies investigated its association with death from MI, and the results remain inconsistent.
Guilt by Emissions
Sanjay Rajagopalan, Jagat Narula
doi : 10.1016/j.jacc.2020.11.032
Volume 77, Issue 3, 26 January 2021, Pages 282-284
Compression Garment Reduces Orthostatic Tachycardia and Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome
Kate M. Bourne, Robert S. Sheldon, Juliette Hall, Matthew Lloyd, ... Satish R. Raj
doi : 10.1016/j.jacc.2020.11.040
Volume 77, Issue 3, 26 January 2021, Pages 285-296
Postural orthostatic tachycardia syndrome (POTS) is a chronic form of orthostatic intolerance associated with a significant symptom burden. Compression garments are a frequently prescribed treatment, but the effectiveness of waist-high compression has not been evaluated in adults with POTS.
Improved Acute Orthostatic Tolerance in POTS by Lower Body Compression: Both Beneficial and Sufficient?
David G. Benditt, Richard Sutton
doi : 10.1016/j.jacc.2020.11.039
Volume 77, Issue 3, 26 January 2021, Pages 297-299
Machine Learning and the Future of Cardiovascular Care: JACC State-of-the-Art Review
Giorgio Quer, Ramy Arnaout, Michael Henne, Rima Arnaout
doi : 10.1016/j.jacc.2020.11.030
Volume 77, Issue 3, 26 January 2021, Pages 300-313
The role of physicians has always been to synthesize the data available to them to identify diagnostic patterns that guide treatment and follow response. Today, increasingly sophisticated machine learning algorithms may grow to support clinical experts in some of these tasks. Machine learning has the potential to benefit patients and cardiologists, but only if clinicians take an active role in bringing these new algorithms into practice. The aim of this review is to introduce clinicians who are not data science experts to key concepts in machine learning that will allow them to better understand the field and evaluate new literature and developments. The current published data in machine learning for cardiovascular disease is then summarized, using both a bibliometric survey, with code publicly available to enable similar analysis for any research topic of interest, and select case studies. Finally, several ways that clinicians can and must be involved in this emerging field are presented.
Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week
Rika Kawakami, Atsushi Sakamoto, Kenji Kawai, Andrea Gianatti, ... Aloke V. Finn
doi : 10.1016/j.jacc.2020.11.031
Volume 77, Issue 3, 26 January 2021, Pages 314-325
To investigate whether severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)–induced myocarditis constitutes an important mechanism of cardiac injury, a review was conducted of the published data and the authors’ experience was added from autopsy examination of 16 patients dying of SARS-CoV-2 infection. Myocarditis is an uncommon pathologic diagnosis occurring in 4.5% of highly selected cases undergoing autopsy or endomyocardial biopsy. Although polymerase chain reaction–detectable virus could be found in the lungs of most coronavirus disease-2019 (COVID-19)–infected subjects in our own autopsy registry, in only 2 cases was the virus detected in the heart. It should be appreciated that myocardial inflammation alone by macrophages and T cells can be seen in noninfectious deaths and COVID-19 cases, but the extent of each is different, and in neither case do such findings represent clinically relevant myocarditis. Given its extremely low frequency and unclear therapeutic implications, the authors do not advocate use of endomyocardial biopsy to diagnose myocarditis in the setting of COVID-19.
2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures
Paul A. Heidenreich, N. A. Mark Estes, Gregg C. Fonarow, Corrine Y. Jurgens, ... Robert L. McNamara
doi : 10.1016/j.jacc.2020.08.037
Volume 77, Issue 3, 26 January 2021, Pages 326-341
Persistence of Left Atrial Appendage Thrombus in Patients With Cardiac Amyloidosis
Edward A. El-Am, Martha Grogan, Ali Ahmad, Sri Harsha Patlolla, ... Vuyisile T. Nkomo
doi : 10.1016/j.jacc.2020.10.057
Volume 77, Issue 3, 26 January 2021, Pages 342-343
